APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drug Conjugate (ADC)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Outlook and Growth Opportunities 2026

Report ID 173992040423 December 2025212 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drug Conjugate (ADC) Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drug Conjugate (ADC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the First in Class (FIC) Antibody Drug Conjugate (ADC) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the First in Class (FIC) Antibody Drug Conjugate (ADC) market include Arvinas, Bayer Corporation, Bicara Therapeutics, Fabhalta, Immatics, Litfulo, Lytgobi, Merus and Ogsiveo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of First in Class (FIC) Antibody Drug Conjugate (ADC) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents First in Class (FIC) Antibody Drug Conjugate (ADC) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the First in Class (FIC) Antibody Drug Conjugate (ADC) market size, projected growth trends, production technologies, key applications, and end-use industries.

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Company

Arvinas

Bayer Corporation

Bicara Therapeutics

Fabhalta

Immatics

Litfulo

Lytgobi

Merus

Ogsiveo

Pumis Biotechnology (BioNTech)

Regeneron Pharmaceuticals

Skyclary

Talvey

Telix

Truqap

Vertex Pharmaceuticals

AstraZeneca

Dizal Pharma

Shanghai Henlius Biotech, Inc.

GSK

Jiangsu Hengrui Medicine

Pfizer

Akeso, Inc

Lixin Pharmaceutical Technology

Johnson & Johnson

Beijing Hotgen Biotech

Suzhou Yilian Biopharmaceutical

Shenzhen Yipusheng

Foreseen Biotechnology

Suzhou Zejing Biopharmaceutical

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type

Small Molecule FIC Drugs

Large Molecule FIC Drugs

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application

Tumors and Cancers

Others

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global First in Class (FIC) Antibody Drug Conjugate (ADC) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions First in Class (FIC) Antibody Drug Conjugate (ADC) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify First in Class (FIC) Antibody Drug Conjugate (ADC) significant trends, drivers, influence factors in global and regions.

6. To analyze First in Class (FIC) Antibody Drug Conjugate (ADC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drug Conjugate (ADC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drug Conjugate (ADC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the First in Class (FIC) Antibody Drug Conjugate (ADC) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global First in Class (FIC) Antibody Drug Conjugate (ADC) industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drug Conjugate (ADC) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of First in Class (FIC) Antibody Drug Conjugate (ADC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of First in Class (FIC) Antibody Drug Conjugate (ADC) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends Table 2. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers Table 3. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges Table 4. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints Table 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Company (2021-2026) Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Company (k units) & (2021-2026) Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Company (2021-2026) Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/unit) of Company (2021-2026) Table 10. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Ranking, (2024-2026) & (USD Million) Table 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Key Company Manufacturing Base & Headquarters Table 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company, Product Type & Application Table 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global First in Class (FIC) Antibody Drug Conjugate (ADC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Small Molecule FIC Drugs Table 18. Significant Companies of Large Molecule FIC Drugs Table 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type (2021-2026) & (k units) Table 21. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type (2027-2032) & (k units) Table 22. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Type (2021-2026) Table 23. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Type (2027-2032) Table 24. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type (2021-2026) Table 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Tumors and Cancers Table 30. Significant Companies of Others Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application (2021-2026) & (k units) Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application (2027-2032) & (k units) Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Application (2021-2026) Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Application (2027-2032) Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application (2021-2026) Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application (2027-2032) Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026) & (k units) Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2021-2026) Table 44. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2027-2032) & (k units) Table 45. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2027-2032) Table 46. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Region (2021-2026) Table 49. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Region (2027-2032) Table 51. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Average Price (USD/unit) by Region (2021-2026) Table 52. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Average Price (USD/unit) by Region (2027-2032) Table 53. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 56. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 58. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2027-2032) Table 59. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Market Share by Country (2021-2026) Table 61. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Market Share by Country (2027-2032) Table 63. Arvinas Company Information Table 64. Arvinas Business Overview Table 65. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 67. Arvinas Recent Development Table 68. Bayer Corporation Company Information Table 69. Bayer Corporation Business Overview Table 70. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 72. Bayer Corporation Recent Development Table 73. Bicara Therapeutics Company Information Table 74. Bicara Therapeutics Business Overview Table 75. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 77. Bicara Therapeutics Recent Development Table 78. Fabhalta Company Information Table 79. Fabhalta Business Overview Table 80. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 82. Fabhalta Recent Development Table 83. Immatics Company Information Table 84. Immatics Business Overview Table 85. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 87. Immatics Recent Development Table 88. Litfulo Company Information Table 89. Litfulo Business Overview Table 90. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 92. Litfulo Recent Development Table 93. Lytgobi Company Information Table 94. Lytgobi Business Overview Table 95. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 97. Lytgobi Recent Development Table 98. Merus Company Information Table 99. Merus Business Overview Table 100. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 102. Merus Recent Development Table 103. Ogsiveo Company Information Table 104. Ogsiveo Business Overview Table 105. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 107. Ogsiveo Recent Development Table 108. Pumis Biotechnology (BioNTech) Company Information Table 109. Pumis Biotechnology (BioNTech) Business Overview Table 110. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 112. Pumis Biotechnology (BioNTech) Recent Development Table 113. Regeneron Pharmaceuticals Company Information Table 114. Regeneron Pharmaceuticals Business Overview Table 115. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 117. Regeneron Pharmaceuticals Recent Development Table 118. Skyclary Company Information Table 119. Skyclary Business Overview Table 120. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 122. Skyclary Recent Development Table 123. Talvey Company Information Table 124. Talvey Business Overview Table 125. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 127. Talvey Recent Development Table 128. Telix Company Information Table 129. Telix Business Overview Table 130. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 132. Telix Recent Development Table 133. Truqap Company Information Table 134. Truqap Business Overview Table 135. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 137. Truqap Recent Development Table 138. Vertex Pharmaceuticals Company Information Table 139. Vertex Pharmaceuticals Business Overview Table 140. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 142. Vertex Pharmaceuticals Recent Development Table 143. AstraZeneca Company Information Table 144. AstraZeneca Business Overview Table 145. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 147. AstraZeneca Recent Development Table 148. Dizal Pharma Company Information Table 149. Dizal Pharma Business Overview Table 150. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 152. Dizal Pharma Recent Development Table 153. Shanghai Henlius Biotech, Inc. Company Information Table 154. Shanghai Henlius Biotech, Inc. Business Overview Table 155. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 157. Shanghai Henlius Biotech, Inc. Recent Development Table 158. GSK Company Information Table 159. GSK Business Overview Table 160. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 162. GSK Recent Development Table 163. Jiangsu Hengrui Medicine Company Information Table 164. Jiangsu Hengrui Medicine Business Overview Table 165. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 167. Jiangsu Hengrui Medicine Recent Development Table 168. Pfizer Company Information Table 169. Pfizer Business Overview Table 170. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 171. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 172. Pfizer Recent Development Table 173. Akeso, Inc Company Information Table 174. Akeso, Inc Business Overview Table 175. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 176. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 177. Akeso, Inc Recent Development Table 178. Lixin Pharmaceutical Technology Company Information Table 179. Lixin Pharmaceutical Technology Business Overview Table 180. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 181. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 182. Lixin Pharmaceutical Technology Recent Development Table 183. Johnson & Johnson Company Information Table 184. Johnson & Johnson Business Overview Table 185. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 186. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 187. Johnson & Johnson Recent Development Table 188. Beijing Hotgen Biotech Company Information Table 189. Beijing Hotgen Biotech Business Overview Table 190. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 191. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 192. Beijing Hotgen Biotech Recent Development Table 193. Suzhou Yilian Biopharmaceutical Company Information Table 194. Suzhou Yilian Biopharmaceutical Business Overview Table 195. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 196. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 197. Suzhou Yilian Biopharmaceutical Recent Development Table 198. Shenzhen Yipusheng Company Information Table 199. Shenzhen Yipusheng Business Overview Table 200. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 201. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 202. Shenzhen Yipusheng Recent Development Table 203. Foreseen Biotechnology Company Information Table 204. Foreseen Biotechnology Business Overview Table 205. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 206. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 207. Foreseen Biotechnology Recent Development Table 208. Suzhou Zejing Biopharmaceutical Company Information Table 209. Suzhou Zejing Biopharmaceutical Business Overview Table 210. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 211. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 212. Suzhou Zejing Biopharmaceutical Recent Development Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors List Table 216. First in Class (FIC) Antibody Drug Conjugate (ADC) Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Image Figure 2. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2032) & (k units) Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Small Molecule FIC Drugs Image Figure 10. Large Molecule FIC Drugs Image Figure 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Type (2021-2032) Figure 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type (2021-2032) Figure 17. Tumors and Cancers Image Figure 18. Others Image Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Application (2021-2032) Figure 22. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application (2021-2032) Figure 25. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 30. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 36. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. S

Scope & coverage.

Types
  • Small Molecule FIC Drugs
  • Large Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Others
Companies covered
  • Arvinas
  • Bayer Corporation
  • Bicara Therapeutics
  • Fabhalta
  • Immatics
  • Litfulo
  • Lytgobi
  • Merus
  • Ogsiveo
  • Pumis Biotechnology (BioNTech)
  • Regeneron Pharmaceuticals
  • Skyclary
  • Talvey
  • Telix
  • Truqap
  • Vertex Pharmaceuticals
  • AstraZeneca
  • Dizal Pharma
  • Shanghai Henlius Biotech, Inc.
  • GSK
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Akeso, Inc
  • Lixin Pharmaceutical Technology
  • Johnson & Johnson
  • Beijing Hotgen Biotech
  • Suzhou Yilian Biopharmaceutical
  • Shenzhen Yipusheng
  • Foreseen Biotechnology
  • Suzhou Zejing Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  4. 1.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume (2021-2032)
  5. 1.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints
3 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Company
  1. 3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Revenue Ranking in 2025
  2. 3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Company (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Company (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price by Company (2021-2026)
  5. 3.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Ranking (2024-2026)
  6. 3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Manufacturing Base and Headquarters
  7. 3.7 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Product Type and Application
  8. 3.8 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 First in Class (FIC) Antibody Drug Conjugate (ADC) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Type
  1. 4.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Type Introduction
  2. 4.1.1 Small Molecule FIC Drugs
  3. 4.1.2 Large Molecule FIC Drugs
  4. 4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type
  5. 4.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type
  9. 4.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Type (2021-2032)
  11. 4.3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type (2021-2032)
5 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Application
  1. 5.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Application Introduction
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Others
  4. 5.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application
  5. 5.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application
  9. 5.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Application (2021-2032)
  11. 5.3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application (2021-2032)
6 First in Class (FIC) Antibody Drug Conjugate (ADC) Regional Sales and Value Analysis
  1. 6.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2032)
  3. 6.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021-2026
  4. 6.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2027-2032)
  5. 6.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region (2021-2032)
  7. 6.4.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region: 2021-2026
  8. 6.4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Region (2027-2032)
  9. 6.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  12. 6.6.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  15. 6.7.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  21. 6.9.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Country, 2025 VS 2032
7 First in Class (FIC) Antibody Drug Conjugate (ADC) Country-level Sales and Value Analysis
  1. 7.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  4. 7.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  5. 7.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032)
  6. 7.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country (2021-2032)
  7. 7.4.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country (2021-2026)
  8. 7.4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arvinas
  2. 8.1.1 Arvinas Company Information
  3. 8.1.2 Arvinas Business Overview
  4. 8.1.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  6. 8.1.5 Arvinas Recent Developments
  7. 8.2 Bayer Corporation
  8. 8.2.1 Bayer Corporation Company Information
  9. 8.2.2 Bayer Corporation Business Overview
  10. 8.2.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  12. 8.2.5 Bayer Corporation Recent Developments
  13. 8.3 Bicara Therapeutics
  14. 8.3.1 Bicara Therapeutics Company Information
  15. 8.3.2 Bicara Therapeutics Business Overview
  16. 8.3.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  18. 8.3.5 Bicara Therapeutics Recent Developments
  19. 8.4 Fabhalta
  20. 8.4.1 Fabhalta Company Information
  21. 8.4.2 Fabhalta Business Overview
  22. 8.4.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  24. 8.4.5 Fabhalta Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Litfulo
  32. 8.6.1 Litfulo Company Information
  33. 8.6.2 Litfulo Business Overview
  34. 8.6.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  36. 8.6.5 Litfulo Recent Developments
  37. 8.7 Lytgobi
  38. 8.7.1 Lytgobi Company Information
  39. 8.7.2 Lytgobi Business Overview
  40. 8.7.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  42. 8.7.5 Lytgobi Recent Developments
  43. 8.8 Merus
  44. 8.8.1 Merus Company Information
  45. 8.8.2 Merus Business Overview
  46. 8.8.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  48. 8.8.5 Merus Recent Developments
  49. 8.9 Ogsiveo
  50. 8.9.1 Ogsiveo Company Information
  51. 8.9.2 Ogsiveo Business Overview
  52. 8.9.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  54. 8.9.5 Ogsiveo Recent Developments
  55. 8.10 Pumis Biotechnology (BioNTech)
  56. 8.10.1 Pumis Biotechnology (BioNTech) Company Information
  57. 8.10.2 Pumis Biotechnology (BioNTech) Business Overview
  58. 8.10.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  60. 8.10.5 Pumis Biotechnology (BioNTech) Recent Developments
  61. 8.11 Regeneron Pharmaceuticals
  62. 8.11.1 Regeneron Pharmaceuticals Company Information
  63. 8.11.2 Regeneron Pharmaceuticals Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 8.12 Skyclary
  68. 8.12.1 Skyclary Company Information
  69. 8.12.2 Skyclary Business Overview
  70. 8.12.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  72. 8.12.5 Skyclary Recent Developments
  73. 8.13 Talvey
  74. 8.13.1 Talvey Company Information
  75. 8.13.2 Talvey Business Overview
  76. 8.13.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  78. 8.13.5 Talvey Recent Developments
  79. 8.14 Telix
  80. 8.14.1 Telix Company Information
  81. 8.14.2 Telix Business Overview
  82. 8.14.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  84. 8.14.5 Telix Recent Developments
  85. 8.15 Truqap
  86. 8.15.1 Truqap Company Information
  87. 8.15.2 Truqap Business Overview
  88. 8.15.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  90. 8.15.5 Truqap Recent Developments
  91. 8.16 Vertex Pharmaceuticals
  92. 8.16.1 Vertex Pharmaceuticals Company Information
  93. 8.16.2 Vertex Pharmaceuticals Business Overview
  94. 8.16.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  96. 8.16.5 Vertex Pharmaceuticals Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
  103. 8.18 Dizal Pharma
  104. 8.18.1 Dizal Pharma Company Information
  105. 8.18.2 Dizal Pharma Business Overview
  106. 8.18.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  108. 8.18.5 Dizal Pharma Recent Developments
  109. 8.19 Shanghai Henlius Biotech, Inc.
  110. 8.19.1 Shanghai Henlius Biotech, Inc. Company Information
  111. 8.19.2 Shanghai Henlius Biotech, Inc. Business Overview
  112. 8.19.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  114. 8.19.5 Shanghai Henlius Biotech, Inc. Recent Developments
  115. 8.20 GSK
  116. 8.20.1 GSK Company Information
  117. 8.20.2 GSK Business Overview
  118. 8.20.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  120. 8.20.5 GSK Recent Developments
  121. 8.21 Jiangsu Hengrui Medicine
  122. 8.21.1 Jiangsu Hengrui Medicine Company Information
  123. 8.21.2 Jiangsu Hengrui Medicine Business Overview
  124. 8.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  126. 8.21.5 Jiangsu Hengrui Medicine Recent Developments
  127. 8.22 Pfizer
  128. 8.22.1 Pfizer Company Information
  129. 8.22.2 Pfizer Business Overview
  130. 8.22.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  132. 8.22.5 Pfizer Recent Developments
  133. 8.23 Akeso, Inc
  134. 8.23.1 Akeso, Inc Company Information
  135. 8.23.2 Akeso, Inc Business Overview
  136. 8.23.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  138. 8.23.5 Akeso, Inc Recent Developments
  139. 8.24 Lixin Pharmaceutical Technology
  140. 8.24.1 Lixin Pharmaceutical Technology Company Information
  141. 8.24.2 Lixin Pharmaceutical Technology Business Overview
  142. 8.24.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  144. 8.24.5 Lixin Pharmaceutical Technology Recent Developments
  145. 8.25 Johnson & Johnson
  146. 8.25.1 Johnson & Johnson Company Information
  147. 8.25.2 Johnson & Johnson Business Overview
  148. 8.25.3 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  150. 8.25.5 Johnson & Johnson Recent Developments
  151. 8.26 Beijing Hotgen Biotech
  152. 8.26.1 Beijing Hotgen Biotech Company Information
  153. 8.26.2 Beijing Hotgen Biotech Business Overview
  154. 8.26.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  156. 8.26.5 Beijing Hotgen Biotech Recent Developments
  157. 8.27 Suzhou Yilian Biopharmaceutical
  158. 8.27.1 Suzhou Yilian Biopharmaceutical Company Information
  159. 8.27.2 Suzhou Yilian Biopharmaceutical Business Overview
  160. 8.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  162. 8.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
  163. 8.28 Shenzhen Yipusheng
  164. 8.28.1 Shenzhen Yipusheng Company Information
  165. 8.28.2 Shenzhen Yipusheng Business Overview
  166. 8.28.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  168. 8.28.5 Shenzhen Yipusheng Recent Developments
  169. 8.29 Foreseen Biotechnology
  170. 8.29.1 Foreseen Biotechnology Company Information
  171. 8.29.2 Foreseen Biotechnology Business Overview
  172. 8.29.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  174. 8.29.5 Foreseen Biotechnology Recent Developments
  175. 8.30 Suzhou Zejing Biopharmaceutical
  176. 8.30.1 Suzhou Zejing Biopharmaceutical Company Information
  177. 8.30.2 Suzhou Zejing Biopharmaceutical Business Overview
  178. 8.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  180. 8.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Analysis
  2. 9.1.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Mode & Process
  6. 9.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors
  9. 9.2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst